{
    "organizations": [],
    "uuid": "5849630d354f85d14fc8037f4c40bd6ab070658a",
    "author": "",
    "url": "https://www.reuters.com/article/brief-lilly-receives-additional-fda-appr/brief-lilly-receives-additional-fda-approval-for-verzenio-idUSL8N1QG7FT",
    "ord_in_thread": 0,
    "title": "BRIEF-Lilly Receives Additional FDA Approval For Verzenio​",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Feb 26 (Reuters) - Eli Lilly And Co:\n* LILLY RECEIVES ADDITIONAL FDA APPROVAL FOR VERZENIO (ABEMACICLIB), AS INITIAL TREATMENT FOR ADVANCED BREAST CANCER\n* SAYS ‍NEW INDICATION BASED ON MONARCH 3 TRIAL CAN HELP MORE WOMEN LIVING WITH HR+, HER2- ADVANCED BREAST CANCER​\n* SAYS ‍RECOMMENDED DOSE OF VERZENIO IN COMBINATION WITH AI IS 150 MG ORALLY TWICE DAILY, CONTINUED UNTIL DISEASE PROGRESSION/ UNACCEPTABLE TOXICITY​\n* SAYS ‍VERZENIO IS AVAILABLE IN 4 TABLET STRENGTHS (200 MG, 150 MG, 100 MG, AND 50 MG)​ Source text for Eikon: Further company coverage:\n ",
    "published": "2018-02-27T01:20:00.000+02:00",
    "crawled": "2018-02-27T01:35:57.010+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "feb",
        "reuters",
        "eli",
        "lilly",
        "co",
        "lilly",
        "receives",
        "additional",
        "fda",
        "approval",
        "verzenio",
        "abemaciclib",
        "initial",
        "treatment",
        "advanced",
        "breast",
        "cancer",
        "say",
        "indication",
        "based",
        "monarch",
        "trial",
        "help",
        "woman",
        "living",
        "advanced",
        "breast",
        "say",
        "dose",
        "verzenio",
        "combination",
        "ai",
        "mg",
        "orally",
        "twice",
        "daily",
        "continued",
        "disease",
        "unacceptable",
        "say",
        "available",
        "tablet",
        "strength",
        "mg",
        "mg",
        "mg",
        "mg",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}